



140
Docket No. 68811-A/JPW/GJG/NDP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Sharon Cohen-Vered, et al.
Serial No. : 10/758,397
Filed : January 14, 2004
For : PARENTERAL FORMULATIONS OF PEPTIDES FOR THE
TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS

1185 Avenue of the Americas
New York, New York 10036
October 13, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following documents which are listed on Form PTO-1449 (**Exhibit A**) and are also listed below. A copy of the references listed below as items 1-7 are attached hereto as **Exhibit 1-7**.

This Information Disclosure Statement is being submitted pursuant to 37 C.F.R. §1.97(b)(3) before the mailing of a first Office Action on the merits. Thus, this Information Disclosure Statement should be entered and considered.

1. PCT International Application Publication No. WO 99/31066 published June 24, 1999 (**Exhibit 1**);

Applicants: Sharon Cohen-Vered, et al.

Serial No.: 10/758,397

Filed: January 14, 2004

Page 2

2. Brosch N. et al. (2000) A Peptide Based on the Sequence of the CDR3 of a Murine Anti-DNA mAb is a Better Modulator of Experimental SLE than its Single Amino Acid-Substituted Analogs. Cellular Immunology, 205:52-61 (**Exhibit 2**);
3. Brosch N. et al. (2000) Characterization and Role in Experimental Systemic Lupus Erythematosus of T-cell Lines Specific to Peptides Based on Complementarity-Determining Region-1 and Complementarity-Determining Region-3 of a Pathogenic Anti-DNA Monoclonal Antibody. Immunology 99:257-264 (**Exhibit 3**);
4. Naparstek, Y. et al. (1989) Sequential Anti-Idiotypes Define Reciprocal Idiotypes on the Same Anti-DNA Antibody. Clinical Immunology and Immunopathology, 50:S106-S116 (**Exhibit 4**);
5. Paemen, L. et al. (1994) Evaluation of gelatinases and IL-6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases. Eur. J. Neurol., 1:55-63 (**Exhibit 5**);
6. Tsokos G.C. et al. (1999) Immune Cell Signaling Defects in Lupus: Activation, Anergy and Death. Immunology Today (**Exhibit 6**); and
7. Waisman, A. et al. (1993) The role of the 16/6 idiotype network in the induction and manifestations of systemic lupus erythematosus. Int. Immunol., 5:1293-300 (**Exhibit 7**).

Applicants: Sharon Eshen-Vered, et al.

Serial No.: 10/758,397

Filed: January 14, 2004

Page 3

Applicants request that the Examiner review the references and make them of record in the subject application.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

Gary J. Gershik

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Gary J. Gershik 10/13/04
John P. White Date
Reg. No. 28,678
Gary J. Gershik
Reg. No. 39,992

John P. White
Registration No. 28,678
Gary J. Gershik
Registration No. 39,992
Attorneys for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)							Atty. Docket No. 68811-A/JPW/GJG/NDP	Serial No. 10/758,397					
							Applicants: Sharon Cohen-Vered et al.						
							Filing Date January 14, 2004	Group					
U.S. PATENT DOCUMENTS													
Examiner Initial		Document Number			Date	Name	Class	Subclass	Filing Date if Appropriate				
FOREIGN PATENT DOCUMENTS													
		Document Number			Date	Country	Class	Subclass	Translation				
		WO	9	9	3	1	0	6	6	6/24/99	PCT;	Yes	No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)													
		Brosch N. et al. (2000) A Peptide Based on the Sequence of the CDR3 of a Murine Anti-DNA mAb is a Better Modulator of Experimental SLE than its Single Amino Acid-Substituted Analogs <i>Cellular Immunology</i> , 205:52-61;											
		Brosch N. et al. (2000) Characterization and Role in Experimental Systemic Lupus Erythematosus of T-cell Lines Specific to Peptides Based on Complementarity-Determining Region-1 and Complementarity-Determining Region-3 of a Pathogenic Anti-DNA Monoclonal Antibody <i>Immunology</i> 99:257-264;											
		Naparstek, Y. et al. (1989) Sequential Anti-Idiotypes Define Reciprocal Idiotypes on the Same Anti-DNA Antibody. <i>Clinical Immunology and Immunopathology</i> , 50:S106-S116;											
		Paemen, L. et al. (1994) Evaluation of gelatinases and IL-6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases. <i>Eur. J. Neurol.</i> 1:55-63;											
		Tsokos G.C. et al. (1999) Immune Cell Signaling Defects in Lupus: Activation, Anergy and Death <i>Immunology Today</i> ; and											
		Waisman, A. et al. (1993) The role of the 16/6 idiotype network in the induction and manifestation of systemic lupus erythematosus. <i>Int. Immunol.</i> , 5:1293-300.											
EXAMINER				DATE CONSIDERED									

Applicants: Sharon Cohen-Vered et al.
Serial No.: 10/758,397
Filed: January 14, 2004
Exhibit A